ABSTRACT
AIMS/HYPOTHESIS: Islet amyloid in type 2 diabetes contributes to loss of beta cell mass and function. Since islets are susceptible to oxidative stress-induced toxicity, we sought to determine whether islet amyloid formation is associated with induction of oxidative stress. METHODS: Human islet amyloid polypeptide transgenic and non-transgenic mouse islets were cultured for 48 or 144 h with or without the antioxidant N-acetyl-L: -cysteine (NAC) or the amyloid inhibitor Congo Red. Amyloid deposition, reactive oxygen species (ROS) production, beta cell apoptosis, and insulin secretion, content and mRNA were measured. RESULTS: After 48 h, amyloid deposition was associated with increased ROS levels and increased beta cell apoptosis, but no change in insulin secretion, content or mRNA levels. Antioxidant treatment prevented the rise in ROS, but did not prevent amyloid formation or beta cell apoptosis. In contrast, inhibition of amyloid formation prevented the induction of oxidative stress and beta cell apoptosis. After 144 h, amyloid deposition was further increased and was associated with increased ROS levels, increased beta cell apoptosis and decreased insulin content. At this time-point, antioxidant treatment and inhibition of amyloid formation were effective in reducing ROS levels, amyloid formation and beta cell apoptosis. Inhibition of amyloid formation also increased insulin content. CONCLUSIONS/INTERPRETATION: Islet amyloid formation induces oxidative stress, which in the short term does not mediate beta cell apoptosis, but in the longer term may feed back to further exacerbate amyloid formation and contribute to beta cell apoptosis.
Subject(s)
Amyloid/biosynthesis , Apoptosis/physiology , Insulin-Secreting Cells/cytology , Insulin-Secreting Cells/physiology , Oxidative Stress/physiology , Amyloid/genetics , Amyloid/physiology , Animals , Diabetes Mellitus, Type 2/physiopathology , Humans , Insulin/genetics , Insulin/metabolism , Insulin Secretion , Insulin-Secreting Cells/metabolism , Islet Amyloid Polypeptide , Mice , Mice, Transgenic , RNA, Messenger/genetics , Reactive Oxygen Species/metabolismABSTRACT
Fibroblast apoptosis plays a crucial role in normal and pathological scar formation and therefore we studied whether the putative apoptosis-inducing factor curcumin affects fibroblast apoptosis and may function as a novel therapeutic. We show that 25-microM curcumin causes fibroblast apoptosis and that this could be inhibited by co-administration of antioxidants N-acetyl-l-cysteine (NAC), biliverdin or bilirubin, suggesting that reactive oxygen species (ROS) are involved. This is supported by our observation that 25-microM curcumin caused the generation of ROS, which could be completely blocked by addition of NAC or bilirubin. Since biliverdin and bilirubin are downstream products of heme degradation by heme oxygenase (HO), it has been suggested that HO-activity protects against curcumin-induced apoptosis. Interestingly, exposure to curcumin maximally induced HO-1 protein and HO-activity at 10-15 microM, whereas, at a concentration of >20-microM curcumin HO-1-expression and HO-activity was negligible. NAC-mediated inhibition of 25-microM curcumin-induced apoptosis was demonstrated to act in part via restored HO-1-induction, since the rescuing effect of NAC could be reduced by inhibiting HO-activity. Moreover pre-induction of HO-1 using 5-microM curcumin protected fibroblasts against 25-microM curcumin-induced apoptosis. On a functional level, fibroblast-mediated collagen gel contraction, an in vitro wound contraction model, was completely prevented by 25-microM curcumin, while this could be reversed by co-incubation with NAC, an effect that was also partially HO-mediated. In conclusion, curcumin treatment in high doses (>25 microM) may provide a novel way to modulate pathological scar formation through the induction of fibroblast apoptosis, while antioxidants, HO-activity and its effector molecules act as a possible fine-tuning regulator.
Subject(s)
Apoptosis/drug effects , Cicatrix/enzymology , Curcumin/pharmacology , Fibroblasts/cytology , Fibroblasts/enzymology , Heme Oxygenase (Decyclizing)/metabolism , Wound Healing/drug effects , Acetylcysteine/pharmacology , Antioxidants/pharmacology , Bilirubin/pharmacology , Collagen/metabolism , Dermis/cytology , Dose-Response Relationship, Drug , Fibroblasts/drug effects , Gels , Glutathione/pharmacology , Humans , Reactive Oxygen Species/metabolismABSTRACT
Syntheses of six new N-(pentopyranosyl)imidazoles have been achieved, and their conformations were observed with and without protonation. A decisive decrease in J(5',4), consistent with stabilization of the 1C4 conformations, was clearly observed for three N-(pentopyranosyl)imidazoles. As well, no reverse anomeric stabilization was observed for N-(2,3,4-tri-O-acetyl-alpha-D-lyxopyranosyl)imidazole upon protonation. It is suggested that the previous observations of the reverse anomeric effect were due to the slight increase in steric bulk of the imidazole aglycone upon protonation, along with favorable dipolar interactions between ring substituents, and not by a reverse of the anomeric effect.
Subject(s)
Carbohydrates/chemistry , Iodine/chemistry , Sulfur/chemistry , Carbohydrate Conformation , Carbohydrate Metabolism , Carbohydrate Sequence , Carbohydrates/chemical synthesis , Cyclization , Glycosylation , Indicators and Reagents/chemistry , Molecular Sequence Data , Molecular Structure , Phosphorus/chemistryABSTRACT
4-Deoxy-4-fluoro analogues of 2-acetamido-2-deoxy-D-glucose and 2-acetamido-2-deoxy-D-galactose were synthesized and evaluated as inhibitors of hepatic glycosaminoglycan biosynthesis. 2-Acetamido-1,3,6-tri-O-acetyl-2,4-dideoxy-4-fluoro-D-glucopyranose (16) exhibited a reduction of [3H]GlcN and [35S]SO4 incorporation into hepatocyte cellular glycosaminoglycans to 12 and 18%, respectively, of the control cells, at 1.0 mM. Similarly, 2-acetamido-1,3,6-tri-O-acetyl-2,4-dideoxy-4-fluoro-D-galactopyranose (31) exhibited a reduction of [3H]GlcN and [35S]SO4 incorporation to 1 and 9%, respectively, of the control cells, at 1.0 mM. Unlike 16, 31 exhibited a reduction of [14C]Leu incorporation into cellular protein to 57% of control cells, at 1.0 mM.
Subject(s)
Acetylglucosamine/chemical synthesis , Galactose/chemical synthesis , Glycosaminoglycans/biosynthesis , Acetylgalactosamine/analogs & derivatives , Acetylglucosamine/analogs & derivatives , Acetylglucosamine/chemistry , Acetylglucosamine/pharmacology , Animals , Cells, Cultured , Female , Galactose/analogs & derivatives , Galactose/pharmacology , Hepatocytes/drug effects , Hepatocytes/metabolism , Magnetic Resonance Spectroscopy , Mice , Molecular Structure , Protein BiosynthesisABSTRACT
4-Deoxy analogues of 2-acetamido-2-deoxy-D-glucose and 2-acetamido-2-deoxy-D-xylose were synthesized and evaluated as inhibitors of glycoconjugate biosynthesis. Methyl 2-acetamido-2,4-dideoxy-beta-D-xylo-hexopyranoside (11) showed a reduction in [3H]GlcN and [14C]Leu incorporation into hepatocyte cellular glycoconjugates by 89 and 88%, of the control cells, respectively, at 20 mM, whereas the free sugars, 2-acetamido-2,4-dideoxy-alpha,beta-D-xylo-hexopyranoses (15), showed a reduction of [3H]GlcN and [14C]Leu incorporation by 75 and 64%, respectively, at 20 mM. The acetylated analogues of 11 and 15, namely methyl 2-acetamido-3,6-di-O-acetyl-2,4-dideoxy-beta-D-xylo-hexopyranoside and 2-acetamido-1,3,6-tri-O-acetyl-2,4-dideoxy-alpha,beta-D-xylo-hexopyra noses, showed a greater inhibition of [3H]GlcN and [14C]Leu incorporation at 1 mM compared with their non-acetylated counterparts, but were toxic to hepatocytes at concentrations of 10 and 20 mM. Corresponding derivatives of 2-acetamido-2,4-dideoxy-L-threo-pentopyranose showed no biological effect up to 20 mM, suggesting that the C-6 substituent is important for the biological activity.
Subject(s)
Deoxy Sugars/chemical synthesis , Glycoconjugates/biosynthesis , Acetylglucosamine/analogs & derivatives , Animals , Carbohydrate Conformation , Cells, Cultured , Deoxy Sugars/pharmacology , Leucine/metabolism , Liver/drug effects , Liver/metabolism , Magnetic Resonance Spectroscopy , Mice , Xylose/analogs & derivativesABSTRACT
Serial transcranial Doppler ultrasonography (TCD) studies were carried out in 61 patients, who had been operated due to supratentorial brain tumours. Among 61 cases have been 26 gliomas, 19 meningiomas and 16 metastases. The Mean Flow Velocity (MFV) exceeding 120 cm/s in Middle Cerebral Artery (MCA) and 90 cm/s in Anterior Cerebral Artery (ACA) has been admitted as pathognomonic for vasospasm. The vasospasm has been stated in 14 cases (23%)--10 gliomas and 4 meningiomas out of 61 patients. The vasospasm has been more intense in ACA on the operated (lesion) side than in MCA and on the non operated (opposite) side.
Subject(s)
Neurosurgical Procedures/adverse effects , Supratentorial Neoplasms/surgery , Vasospasm, Intracranial/diagnostic imaging , Vasospasm, Intracranial/etiology , Adolescent , Adult , Aged , Blood Flow Velocity , Cerebrovascular Circulation , Child , Child, Preschool , Follow-Up Studies , Glioma/surgery , Humans , Incidence , Meningioma/surgery , Middle Aged , Postoperative Period , Prospective Studies , Supratentorial Neoplasms/secondary , Ultrasonography, Doppler, Transcranial , Vasospasm, Intracranial/epidemiology , Vasospasm, Intracranial/physiopathologyABSTRACT
The aim of the study was to evaluate the influence of intracerebral haematoma due to aneurysmal rupture on vasospasm evaluated by transcranial Doppler ultrasound and outcome according to Glasgow Outcome Scale. 368 patients with ruptured intracranial aneurysm were admitted to the Department of Neurosurgery, Medical Academy in Wroclaw, between January 1, 1995 and June 30, 1998. Patients were divided into two groups. In group I there were 74 patients with subarachnoid haemorrhage and intracerebral haematoma. In group II 294 patients with subarachnoid haemorrhage. Despite intensive monitoring and treatment the outcome of patients with subarachnoid haemorrhage and intracerebral haematoma is worse than in patients with subarachnoid haemorrhage only.
Subject(s)
Aneurysm, Ruptured/diagnostic imaging , Hematoma, Subdural/diagnostic imaging , Intracranial Aneurysm/diagnostic imaging , Ultrasonography, Doppler, Transcranial/methods , Adolescent , Adult , Aged , Aneurysm, Ruptured/complications , Cerebral Angiography/methods , Disease Progression , Female , Glasgow Coma Scale , Hematoma, Subdural/etiology , Humans , Intracranial Aneurysm/complications , Male , Middle Aged , Retrospective Studies , Vasoconstriction/physiologyABSTRACT
The coupling of 2,3,6,2',3',4',6-hepta-O-acetyl-alpha-lactosyl bromide with 1,4-di-O-benzyl-D-threitol using mercury(II) cyanide as a promoter, with subsequent deprotection of one or both of the benzyl groups, further glycosylation, and deacetylation afforded the title compounds. This class of compound is useful in the assessment of binding properties of D-galactopyranose to human and rabbit hepatocytes.
Subject(s)
Lactose/analogs & derivatives , Acetylation , Carbohydrate Sequence , Glycosylation , Lactose/chemical synthesis , Molecular Sequence DataABSTRACT
In experimental murine inflammation-associated amyloidosis (AA amyloidosis), an interaction between heparan sulfate and serum amyloid A (SAA), the AA precursor, has been demonstrated and is believed to play an important role in AA amyloidogenesis. Poly(vinylsulfonate) sodium salt (PVS) can arrest AA amyloid induction and cause established amyloid deposits to regress. PVS is thought to have this property by virtue of limited anionic structural similarities it has to heparan sulfate. In the present study, a comparison has been made of the in situ light microscopic and high-resolution ultrastructure of amyloid deposits before and after PVS treatment. As shown recently in situ, AA fibrils from untreated mice are composed of an outer layer of heparan sulfate proteoglycan and a 1- to 2-nm filament network of AA protein. This layer encloses a microfibril-like structure composed of chondroitin sulfate proteoglycan wound around a core of amyloid P component. After treatment with PVS, both the heparan sulfate proteoglycan and the AA filament network are lost from the fibrils, and the more central portion disintegrates into the chondroitin sulfate proteoglycan with associated amyloid P subunits. These findings add further support to the concept that heparan sulfate proteoglycan is important in amyloid fibril structure, and interference with its binding interactions with the amyloid filament protein provides a point of therapeutic attack.
Subject(s)
Polyvinyls/pharmacology , Serum Amyloid A Protein/drug effects , Serum Amyloid A Protein/ultrastructure , Sulfonic Acids/pharmacology , Amyloidosis/metabolism , Amyloidosis/pathology , Amyloidosis/prevention & control , Animals , Female , Mice , Mice, Inbred Strains , Polyvinyls/therapeutic use , Serum Amyloid A Protein/antagonists & inhibitors , Spleen/chemistry , Spleen/drug effects , Sulfonic Acids/therapeutic useABSTRACT
An improved, convenient synthesis of 3-deoxy-D-xylo-hexose (3-deoxy-D-galactose) has been developed, and the chemical synthesis of a novel monosaccharide derivative, methyl (methyl 4-chloro-4-deoxy-beta-D-galactopyranosid)uronate (compound 10), is described. Using primary hepatocytes in culture, each was used to explore its effect on glycosaminoglycan (GAG) synthesis. In the absence of analogues hepatocytes synthesize primarily (92-95%) heparan sulphate. At 1 mM, 3-deoxy-D-galactose had little observable effect on either liver cell GAG or protein synthesis. At 10 mM and 20 mM, 3-deoxy-D-galactose reduced [3H]glucosamine and 35SO4 incorporation into hepatocyte cellular GAGs to, respectively, 75% and 60% of the control cells. This inhibition of GAG synthesis occurred without any effect on hepatocyte protein synthesis, indicating that 3-deoxy-D-galactose's effect on GAG synthesis is not mediated through an inhibition of proteoglycan core protein synthesis. Furthermore, GAGs in the presence of 20 mM of the analogue were significantly reduced in size, 17 kDa vs. 66 kDa in untreated cells. These results reflect either impaired cellular GAG chain elongation, and/or altered GAG chain degradation. Compound 10 exhibited a concentration-dependent inhibition of both hepatocyte cellular GAG and protein synthesis. At concentrations of 5, 10 and 20 mM, compound 10 inhibited GAG and protein synthesis by 20, 65 and 90%, respectively. Exogenous uridine was able to restore partially the inhibition of protein synthesis, but was unable to reverse the effect of compound 10 on GAG synthesis. These results show that part of the effect of compound 10 on GAG synthesis is not mediated by an inhibition of proteoglycan core protein synthesis. GAGs in the presence of compound 10 are half as large as those in the absence of this compound (33 and 66 kDa, respectively). These results again may reflect either impaired cellular GAG chain elongation and/or altered GAG chain degradation. Potential metabolic routes for each analogue's effect are presented.
Subject(s)
Galactose/analogs & derivatives , Galactosides/pharmacology , Glycosaminoglycans/biosynthesis , Hexuronic Acids/pharmacology , Liver/metabolism , Animals , Cells, Cultured , Female , Galactose/chemical synthesis , Galactose/pharmacology , Galactosides/chemical synthesis , Glycosaminoglycans/chemistry , Hexuronic Acids/chemical synthesis , Liver/cytology , Liver/drug effects , Mice , Molecular Weight , Protein Biosynthesis , Uridine/pharmacologyABSTRACT
Amyloid is a term for extracellular protein fibril deposits that have characteristic tinctorial and structural properties. Heparan sulphate, or the heparan sulphate proteoglycan perlecan, has been identified in all amyloids and implicated in the earliest stages of inflammation-associated (AA) amyloid induction. Heparan sulphate interacts with the AA amyloid precursor and the beta-peptide of Alzheimer's amyloid, imparting characteristic secondary and tertiary amyloid structural features. These observations suggest that molecules that interfere with this interaction may prevent or arrest amyloidogenesis. We synthesized low-molecular-weight (135-1,000) anionic sulphonate or sulphate compounds. When administered orally, these compounds substantially reduced murine splenic AA amyloid progression. They also interfered with heparan sulphate-stimulated beta-peptide fibril aggregation in vitro.
Subject(s)
Alkanesulfonates/therapeutic use , Amyloidosis/drug therapy , Serum Amyloid A Protein/drug effects , Sulfates/therapeutic use , Acute Disease , Alkanesulfonates/chemical synthesis , Alkanesulfonates/toxicity , Alzheimer Disease/drug therapy , Amyloidosis/chemically induced , Animals , Anions , Chronic Disease , Glycols/chemical synthesis , Glycols/therapeutic use , Glycols/toxicity , Heparitin Sulfate/pharmacology , Mice , Polyvinyls/chemistry , Polyvinyls/therapeutic use , Polyvinyls/toxicity , Serum Amyloid A Protein/analysis , Serum Amyloid A Protein/metabolism , Serum Amyloid A Protein/ultrastructure , Spleen/pathology , Sulfates/chemical synthesis , Sulfates/toxicityABSTRACT
The binding affinities of a series of D-galactose-terminated glycerol glycosides and oligosaccharides for the asialoglycoprotein receptor isolated from rabbit liver were determined in vitro using a radioreceptor-inhibition assay with 125I-asialoorosomucoid. The relative affinities of the synthetic ligands increased with the number of exposed D-galactose termini. Of the compounds examined, 1,2,3-tri-O-beta-lactosylglycerol associated with the greatest affinity (estimated Kd = 7.97 x 10(-5) M). Examination of the affinities of the synthetic series indicated that both the number and propinquity of the D-galactose termini influenced the strength of the binding interactions.
Subject(s)
Galactose , Ligands , Liver/metabolism , Oligosaccharides/chemistry , Oligosaccharides/metabolism , Receptors, Cell Surface/metabolism , Animals , Asialoglycoprotein Receptor , Asialoglycoproteins/metabolism , Binding, Competitive , Carbohydrate Conformation , Carbohydrate Sequence , Iodine Radioisotopes , Kinetics , Molecular Sequence Data , Oligosaccharides/pharmacology , Orosomucoid/analogs & derivatives , Orosomucoid/metabolism , Rabbits , Receptors, Cell Surface/drug effects , Receptors, Cell Surface/isolation & purificationABSTRACT
A novel carbohydrate, 4-deoxy-L-threo-pentose (4-deoxyxylose), was synthesized by way of reductive dechlorination of a chlorodeoxy sugar. This carbohydrate, an analogue of xylose which is required for the initiation of glycosaminoglycan (GAG) synthesis, was used to explore the function of GAG side chains in neurite outgrowth on a laminin substrate. 4-Deoxyxylose inhibited the incorporation of 35SO4 into the GAGs of neuronal and astrocytic proteoglycans, with no effect being seen on the incorporation of [3H]glucosamine into proteoglycan. Direct analysis of the heparan sulphate fraction from such cells using nitrous acid digestion confirmed that the GAGs were undersulphated. No inhibition of either 35SO4 or [3H]glucosamine incorporation was observed in primary mouse hepatocytes exposed to 4-deoxyxylose. 4-Deoxyxylose produced a direct dose-dependent inhibition of neurite outgrowth by sensory neurons, and medium conditioned by neurons or astrocytes in the presence of 4-deoxyxylose displayed less laminin-complexed neurite-promoting activity than medium conditioned in its absence. These data suggest that 4-deoxyxylose inhibits neurite outgrowth by altering the sulphation of the GAGs of heparan sulphate proteoglycans.
Subject(s)
Neurons/drug effects , Proteoglycans/biosynthesis , Xylose/analogs & derivatives , Animals , Animals, Newborn , Astrocytes/drug effects , Glycosaminoglycans/biosynthesis , Liver/drug effects , Liver/metabolism , Neurons/metabolism , Rats , Xylose/chemical synthesis , Xylose/pharmacologyABSTRACT
1,2,3,2',3',4',6'-Hepta-O-acetyl-beta-lactose (4) was coupled with 2,3,6,2',3',4',6'-hepta-O-acetyl-alpha-lactosyl bromide (7) in the presence of Hg(CN)2 to afford 1,2,3,2',3',4',6'-hepta-O-acetyl-6-O-(2,3,6,2',3',4',6'-hepta-O-acetyl-b eta- lactosyl)-beta-lactose (11) which, upon O-deacetylation, gave 6-O-beta-lactosyl-alpha,beta-lactoses (64% from 4). In contrast, the reaction of 7 with benzyl 2,3,2',3',4',6'-hexa-O-acetyl-beta-lactoside in the presence of Hg(CN)2 produced 3,6,2',3',4',6'-hexa-O-acetyl-1,2-O- (2,3,2',3',4',6'-hexa-O-acetyl-1-O-benzyl-beta-lactos-6-yl orthoacetyl)-alpha-lactose (63%) and 3,6,2',3',4',6'-hexa-O-acetyl-1,2-O-(1- cyanoethylidene)-alpha-lactose (27%). The glycosidation of 4 using 2,3,4,6-tetra-O-acetyl-alpha-D-galactopyranosyl bromide in the presence of Hg(CN)2 afforded, after deprotection, 4,6-di-O-beta-D-galactopyranosyl-alpha,beta-D-glucoses (66%). The reaction of 11 with 1,2-di-O-benzyl-(R,S)-glycerols and trimethylsilyl trifluoromethanesulfonate yielded, after deprotection, 1-O-(6-O-beta-lactosyl-beta-lactosyl)-(R,S)-glycerols (18%). Under the same coupling conditions 11 reacted with 2-O-benzylglycerol to form 3-O-acetyl-2-O-benzyl-1-O-[2',3',4',6'-hexa-O-acetyl-6-O-(2,3,6,2',3',4' ,6'- hepta-O-acetyl-beta-lactosyl)-beta-lactosyl]-(R,S)-glycerols (16%).
Subject(s)
Glycerides/chemistry , Lactose/chemistry , Lipopolysaccharides/chemistry , Asialoglycoprotein Receptor , Diglycerides/chemistry , Glycosides/chemistry , Magnetic Resonance Spectroscopy , Molecular Sequence Data , Receptors, Immunologic/metabolism , Triglycerides/chemistryABSTRACT
The reaction of 2,3,6,2',3',4',6'-hepta-O-acetyl-alpha-lactosyl bromide (4) and benzyl 3,4-di-O-benzyl-alpha-D-mannopyranoside (3) in the presence of mercury(II) cyanide in benzene-nitromethane produced benzyl 3,4-di-O-benzyl-2,6-bis-O-(2,3,6,2',3',4',6'-hepta-O-acetyl-beta-lact osy l)-alph a D-mannopyranoside (5) and benzyl 3,4-di-O-benzyl-6-O-(2,3,6,2',3',4',6'-hepta-O-acetyl-beta-lactosyl)-alp ha-D- mannopyranoside (6), as part of a complex mixture. Column chromatography, followed by acetylation of the fraction containing 5 and 6, gave a sample of 5 and benzyl 2-O-acetyl-3,4-di-O-benzyl-6-O (2,3,6,2',3',4',6'-hepta-O-acetyl-beta-lactosyl)-alpha-D-mannopyranoside (7) in approximately 35% and 17% yields (based on 4), respectively. Deprotection of 5 and 7 afforded the target compounds, namely 2,6-di-O-beta-lactosyl-alpha,beta-D-mannopyranoses and 6-O-beta-lactosyl-alpha,beta-D-mannopyranoses, respectively. If the coupling of 4 with 3 were performed in the presence of silver trifluoromethanesulfonate and 2,4,6-trimethylpyridine, only a mixture of 3,6,2',3',4',6'-hexa-O-acetyl- alpha-lactose-1,2-[( 3,6,2',3',4',6'-hexa-O-acetyl-alpha-lactose 1,2-(benzyl 3,4-di-O-benzyl-alpha-D-mannopyranosid-6-yl orthoacetyl)-2-yl]orthoacetate) and 3,6,2',3',4',6'-hexa-O-acetyl-alpha-lactose 1,2-(benzyl 3,4-di-O-benzyl-alpha-D-mannopyranosid-6-yl orthoacetate) was obtained. The orthoacetates were characterized by n.m.r. spectroscopy. The two target materials are useful in the assessment of the binding properties of galactose-terminated ligands to the asialoglycoprotein receptor of normal rabbit and human hepatocytes.
Subject(s)
Glycosides/chemical synthesis , Lactose/analogs & derivatives , Mannose/analogs & derivatives , Carbohydrate Sequence , Molecular Sequence DataABSTRACT
An oxonium ion at m/z317 is present in the desorption electron ionization and ammonia desorption chemical ionization mass spectra of peracetylated disaccharides, comprised of glucopyranose units linked (1-->2), (1-->3), (1-->4) and (1-->6), but is absent in the spectra of the (1-->1)-linked isomer. The ion at m/z317, which is derived from the reducing moiety, has an O-formyl group at the position of linkage to the non-reducing moiety, and O-acetyl groups at each of the remaining positions. The isomeric monoformyl, triacetyl oxonium ions (at m/z317), derived from the (1-->2)-, (1-->3)-, (1-->4)- and (1-->6)-linked disaccharides, give distinctly different mass-analysed ion kinetic energy spectra, thereby enabling the linkage position to be assigned unambiguously.
Subject(s)
Disaccharides/analysis , Glycosides/analysis , Acetylation , Carbohydrate Conformation , Electrochemistry , Mass SpectrometryABSTRACT
The reaction of 2,3,6,2',3',4',6'-hepta-O-acetyl-alpha-lactosyl bromide (5) and 1,3-di-O-benzylglycerol in the presence of mercury(II) cyanide in benzene-nitromethane afforded 1,3-di-O-benzyl-2-O-(2,3,6,2',3',4',6'-hepta-O-acetyl-beta-lactosyl)glyc erol (70%), which was converted into 2-O-beta-lactosylglycerol. 1,2-Di-O-beta-lactosyl-(R,S)-glycerols were obtained by way of the coupling of 5 to either 1-O-benzyl-(R,S)-glycerol or 1-O-benzyl-2-O-(2,3,6,2',3',4',6'-hepta-O-acetyl-beta-lactosyl)-(R,S)-gl ycerols. The most efficient route to 1,2, 3-tri-O-beta-lactosylglycerol (17) involved treatment of 2-O-(2,3,6,2',3',4',6'-hepta-O-acetyl-beta-lactosyl)glycerol with 3 mol. equiv. of 5 followed by removal of the blocking groups, to give 17 (47%).
Subject(s)
Glycerol/chemistry , Lactose/chemistry , Carbohydrate Sequence , Molecular Sequence Data , Receptors, Cell Surface/metabolismABSTRACT
Under conditions of desorption-chemical ionization or fast-atom-bombardment mass-spectrometry, the azido groups in some carbohydrate derivatives and other substances undergo apparent reduction to amino groups. Experimental evidence is provided to corroborate the reduction, and possible explanations are proposed for the phenomenon.